New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

AGEs Polyclonal Antibody, APC-Cy5.5 Conjugated

Applications

  • WB
  • FCM
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Human
  • Mouse
  • Rat
Overview
Catalog # bs-1158R-APC-Cy5.5
Product Name AGEs Polyclonal Antibody, APC-Cy5.5 Conjugated
Applications WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC)
Specificity Reacts with BSA-AGE.
Reactivity Human, Mouse, Rat
Specifications
Conjugation APC-Cy5.5
Host Rabbit
Source AGEs
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 280717
Swiss Prot P02769
Subcellular location Secreted
Synonyms Advanced Glycation End products; Serum albumin; BSA; ALB
Background Advanced Glycation End products (AGEs) are the result of a chain of chemical reactions after an initial glycation reaction. The intermediate products are known, variously, as Amadori, Schiff base and Maillard products, named after the researchers who first described them. (The literature is inconsistent in applying these terms. For example, Maillard reaction products are sometimes considered intermediates and sometimes end products.) Side products generated in intermediate steps may be oxidizing agents (such as hydrogen peroxide), or not (such as beta amyloid proteins). "Glycosylation" is sometimes used for "glycation" in the literature, usually as 'non-enzymatic glycosylation. The AGE-modified BSA was produced by reacting BSA with glycolaldehyde under sterile conditions followed by extensive dialysis and purification steps.
Application Dilution
WB 1:300-5000
FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200